Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Otis W. Brawley"'
Autor:
Ahmedin Jemal, Otis W. Brawley, Stacey A. Fedewa, Kevin J. Cullen, J. Leonard Lichtenfeld, Farhad Islami, Richard C. Wender, Jiemin Ma
Publikováno v:
CA: A Cancer Journal for Clinicians. 69:351-362
A summary evaluation of the 2015 American Cancer Society (ACS) challenge goal showed that overall US mortality from all cancers combined declined 26% over the period from 1990 to 2015. Recent research suggests that US cancer mortality can still be lo
Minimizing the burden of cancer in the United States: Goals for a high-performing health care system
Publikováno v:
CA: A Cancer Journal for Clinicians. 69:166-183
Between 1991 and 2015, the cancer mortality rate declined dramatically in the United States, reflecting improvements in cancer prevention, screening, treatment, and survivorship care. However, cancer outcomes in the United States vary substantially b
Publikováno v:
CA: A Cancer Journal for Clinicians. 69:50-79
From the mid-20th century, accumulating evidence has supported the introduction of screening for cancers of the cervix, breast, colon and rectum, prostate (via shared decisions), and lung. The opportunity to detect and treat precursor lesions and inv
Autor:
Kassandra I. Alcaraz, Corinne R. Leach, Rachel S. Cannady, Otis W. Brawley, Kim D. Miller, Tenbroeck Smith, Richard C. Wender, Catherine M. Alfano
Publikováno v:
CA: A Cancer Journal for Clinicians. 69:35-49
Cancer care delivery is being shaped by growing numbers of cancer survivors coupled with provider shortages, rising costs of primary treatment and follow-up care, significant survivorship health disparities, increased reliance on informal caregivers,
Autor:
Lauren R. Teras, Eric J. Jacobs, Otis W. Brawley, Jeffrey Drope, Clifford E Douglas, Alpa V. Patel, Richard C. Wender, Susan M. Gapstur, Marjorie L. McCullough
Publikováno v:
CA: A Cancer Journal for Clinicians. 68:446-470
In the United States, it is estimated that more than 1.7 million people will be diagnosed with cancer, and more than 600,000 will die of the disease in 2018. The financial costs associated with cancer risk factors and cancer care are enormous. To sub
Autor:
Anthony De Felice, Lin Wang, Hwanhee Hong, Lori Rosman, Otis W. Brawley, G. Caleb Alexander, Channing J. Paller
Publikováno v:
J Natl Cancer Inst
Background For nonmetastatic castration-resistant prostate cancer (nmCRPC), 3 drugs under patent protection—apalutamide, enzalutamide, and darolutamide—were approved based on randomized, placebo-controlled trials; 1 drug with generic availability
Autor:
Anthony De Felice, Lin Wang, Hwanhee Hong, G. Caleb Alexander, Channing J. Paller, Otis W. Brawley
Publikováno v:
JAMA Oncol
Importance Multiple systemic treatments are available for metastatic castration-sensitive prostate cancer (mCSPC), with unclear comparative effectiveness and safety and widely varied costs. Objective To compare the effectiveness and safety determined
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17e5d83ae2989adcbf2736fe61e7beed
https://europepmc.org/articles/PMC7809610/
https://europepmc.org/articles/PMC7809610/
Publikováno v:
CA: A Cancer Journal for Clinicians. 68:329-339
This article summarizes cancer mortality trends and disparities based on data from the National Center for Health Statistics. It is the first in a series of articles that will describe the American Cancer Society's vision for how cancer prevention, e
Autor:
Robert A. Smith, Debbie Saslow, Richard C. Wender, Durado Brooks, Otis W. Brawley, Stacey A. Fedewa, Kimberly S. Andrews, Deana Manassaram-Baptiste
Publikováno v:
CA: A Cancer Journal for Clinicians. 68:297-316
Each year, the American Cancer Society publishes a summary of its guidelines for early cancer detection, data and trends in cancer screening rates from the National Health Interview Survey, and select issues related to cancer screening. In this 2018
Autor:
Deana Manassaram-Baptiste, Samuel J. LaMonte, Timothy R. Church, Louise C. Walter, Richard C. Wender, Matthew T. McKenna, Andrew M.D. Wolf, Ruth Etzioni, Rebecca L. Siegel, Ya Chen Tina Shih, Otis W. Brawley, Elizabeth T. H. Fontham, Kevin C. Oeffinger, Kimberly S. Andrews, Durado Brooks, Carmen Guerra, Robert A. Smith, Stacey A. Fedewa, Christopher R. Flowers
Publikováno v:
CA: A Cancer Journal for Clinicians. 68:250-281
In the United States, colorectal cancer (CRC) is the fourth most common cancer diagnosed among adults and the second leading cause of death from cancer. For this guideline update, the American Cancer Society (ACS) used an existing systematic evidence